About: http://data.cimple.eu/news-article/dc4abe1c60fb3f3db18aef5a23967ff76d4902ea554bd2352a9ab5e3     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

AttributesValues
rdf:type
schema:articleBody
  • German firm BioNTech said Thursday that patent protection for Covid-19 vaccines is not holding back production or supply of the jabs that it developed with Pfizer. "Patents are not the limiting factor for the production or supply of our vaccine. They would not increase the global production and supply of vaccine doses in the short and middle term," it told AFP in a statement, in a tacit rejection of a call from the United States to waive patent protections for Covid vaccines. Rather it was issues ranging from the set up of manufacturing sites to the sourcing of raw materials to the availability of qualified personnel that were holding up the process. "If any of these requirements is not met, the quality, safety and efficacy of the vaccine cannot be ensured by the manufacturer nor the innovator. This could put the health of the vaccinees at risk," warned the company. Underlining the minute details that could jeopardise production, the Mainz-based company said that if some of the "limited and important raw materials" are not used in the most efficient manner, it could lead to fewer vaccine doses being manufactured. BioNTech said it has been already able to ramp up supply by entering into licensing and manufacturing partnerships with other pharmaceutical companies such as Merck, Novartis and Sanofi. It argued that further expansion of such cooperation would "help to end this pandemic by ensuring worldwide supply with safe and effective vaccines". BioNTech/Pfizer's vaccine became the first Covid-19 jab to be approved for use in the West late last year. It is now supplying more than 90 countries worldwide, and is expecting to ramp up its production to up to three billion doses by the end of the year from 2.5 billion doses expected previously. The pace will further accelerate to more than three billion doses in 2022. ilp-hmn/mfp/dl
schema:headline
  • Patents not 'limiting factor' for vaccine production: BioNTech
schema:mentions
schema:author
schema:datePublished
http://data.cimple...sPoliticalLeaning
http://data.cimple...logy#hasSentiment
http://data.cimple...readability_score
Faceted Search & Find service v1.16.115 as of Oct 09 2023


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software